Minerva Neurosciences (NASDAQ:NERV) Announces Earnings Results

Minerva Neurosciences (NASDAQ:NERV) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.57, Zacks reports.

Minerva Neurosciences Trading Down 5.6%

Shares of NASDAQ:NERV opened at $1.54 on Thursday. Minerva Neurosciences has a 12-month low of $1.15 and a 12-month high of $3.69. The company has a market cap of $10.76 million, a PE ratio of -3.50 and a beta of -0.50. The stock has a 50 day moving average of $1.62 and a 200 day moving average of $1.98.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on NERV shares. HC Wainwright reaffirmed a “neutral” rating and set a $5.00 price objective on shares of Minerva Neurosciences in a research report on Wednesday, February 26th. StockNews.com initiated coverage on Minerva Neurosciences in a report on Tuesday. They set a “sell” rating on the stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.